The effect air and noise pollution can have on the development of neurodegenerative diseases is not fully understood, but results from a large study published in The Lancet suggest living close to heavy-traffic roadways could increase the risk of developing dementia — but not other neurological diseases, such as multiple sclerosis (MS)…

B-Temia announced the launch of its “b-Klinic Mobility” business unit, offering clinical services, information, training, and ongoing support to patients and healthcare professionals who use the company’s Keeogo walking assistive device. Keeogo is B-Temia’s first product in the class of dermoskeletons, designed to assist persons with mobility-related challenges that limit…

The Multiple Sclerosis Society of Canada (MSSC) recently announced that five university students — either diagnosed with or affected by multiple sclerosis (MS) — were the 2016 recipients of scholarships worth up to $350,000 in tuition and other school-related expenses. All five winners will receive the support throughout the four years of their undergraduate degrees, which are…

The Government of New Brunswick added  Lemtrada (alemtuzumab), by Sanofi Genzyme, to the New Brunswick Prescription Drug Program (NBPDP) through special authorization for eligible patients with relapsing-remitting multiple sclerosis (RRMS). New Brunswick joins other Canadian provinces, including Ontario, Saskatchewan, Quebec, and Manitoba, in making this treatment available to RRMS patients, ages 18 and older, who have had…

The Quebec Division of the Multiple Sclerosis Society of Canada (MSSC)  announced that this year’s 27th Medavie Blue Cross MS Bike, a fundraising bike ride on roads alongside St. Lawrence River, will take place Aug. 27 and 28 in the Mauricie region. A total of 900 cyclists are set to participate in…

Health Canada has approved Teva Canada Innovation‘s three-time weekly 40 mg/mL injection of Copaxone (glatiramer acetate) that allows less frequent dosing for patients with relapsing-remitting multiple sclerosis (RRMS). The approval was grounded primarily on data resulting from the Phase 3 Glatiramer Acetate Low-Frequency Administration (GALA) study, the largest Copaxone clinical…

An entry in the comments section of Multiple Sclerosis News Today caught my attention a couple of weeks ago, and peaked my interest. It was a personal tale of one woman’s journey from being paralyzed and told that her condition was “between you and God” to being able to walk again, thanks to HSCT.

A new report by the Conference Board of Canada’s Canadian Alliance for Sustainable Health Care (CASHC) notes that employers and the Canadian government are not giving enough support towards increasing workforce participation among patients with multiple sclerosis (MS), despite the clear benefits such support would mean to not only the well-being of individuals…

A new Canadian study, published in the International Journal of MS Care, has concluded that the majority of patients with concurrent multiple sclerosis (MS) and depression are receiving antidepressant treatment. Despite this, however, many of these patients continue to report depressive symptoms. MS and depression co-occurrence is…

Genzyme Canada has announced that Health Canada has approved its 14 mg dose of AUBAGIO as an expedited exception benefit product through the federal health regulator’s Non-Insured Health Benefits (NIHB) Program for eligible First Nations people and Inuit as a first-line oral tablet therapy for relapsing remitting multiple sclerosis (RRMS).

The Canadian Drug Expert Committee (CDEC) recently recommended that LEMTRADA (alemtuzumab) be included in provincial and other public drug plans for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS). The recommendation was made through Canada’s Common Drug Review (CDR) and announced in a press release by the company that…

Canadian province Prince Edward Island (PEI) has approved the inclusion of Aubagio (teriflunomide) 14 mg in the PEI Pharmacare’s provincial drug formulary. This means that the drug developed and commercialized by Genzyme is now financially supported by the state as a first-line oral tablet to treat patients who…

Genzyme, a Sanofi company with over 30 years of dedication to researching and developing novel treatments for rare and orphan diseases, has just announced the Alberta Drug Program has finally decided to include Aubagio® (teriflunomide) 14mg in the provincial drug formulary, indicated for the first-line…

Deepelling International conferences on multiple sclerosis (MS) typically gather the most accomplished experts and leading biotech companies under one roof to exchange discoveries and celebrate new hope for MS patients all over the world. Quebec is one of North America’s epicenters for MS research and developments. This year, on…